Pyrotinib, a pan-ERBB tyrosine kinase inhibitor, was found to have an objective response rate (determined by an independent committee using RECIST) of 30% in patients with advanced NSCLC who had previously received platinum-based chemotherapy12, demonstrating potential utility in screening for HER2 mutations in NSCLC of all stages. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.